Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 501–600 of 1,001

Chiral Flavonoids as Antitumor Agents
Pinto, C. A., Cidade, H. M., Pinto, M. M. M., & Tiritan, M. E. (2021) · Pharmaceuticals · doi:10.3390/ph14121267 · Cited by 35
The Role of Circular RNAs in the Drug Resistance of Cancers
Liu, X., Zhang, Q., Guo, J., Zhang, P., Liu, H., Tian, Z., Zhang, C., & Li, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.790589 · Cited by 36
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance
Zhang, C., Wang, C., Yang, Z., Bai, Y., Shukuya, T., Poh, M. E., Ekman, S., Li, J., Xu, Y., & Deng, S. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-318 · Cited by 40
Overcoming multidrug resistance through targeting ABC transporters: lessons for drug discovery
Feyzizadeh, M., Barfar, A., Nouri, Z., Sarfraz, M., Zakeri‐Milani, P., & Valizadeh, H. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2112666 · Cited by 37
On-demand targeting nanotheranostics with stimuli-responsive releasing property to improve delivery efficiency to cancer
Lu, H., Xu, J., Yang, J., Wang, Z., Xu, P., Hao, Q., Luo, W., Li, S., Li, Z., Xue, X., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121852 · Cited by 36
Metabolic Reprogramming: A Friend or Foe to Cancer Therapy?
McCann, C. K., & Kerr, E. M. (2021) · Cancers · doi:10.3390/cancers13133351 · Cited by 36
DNA damage and metabolic mechanisms of cancer drug resistance
Tiek, D. M., & Cheng, S. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.148 · Cited by 39
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
de Bartolomeis, A., Ciccarelli, M., Vellucci, L., Fornaro, M., Iasevoli, F., & Barone, A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2145884 · Cited by 38
Sublethal engagement of apoptotic pathways in residual cancer
Killarney, S. T., Tait, S. W. G., Green, D. R., & Wood, K. C. (2023) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.07.005 · Cited by 35
Targeting AKR1B1 inhibits metabolic reprogramming to reverse systemic therapy resistance in hepatocellular carcinoma
Wang, Q., Liu, J., Yang, M., Zhou, J., Li, Y., Zheng, J., Jia, H., Yue, S., Le, Y., Su, Y., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02321-9 · Cited by 35
Plasma treatment causes structural modifications in lysozyme, and increases cytotoxicity towards cancer cells
Attri, P., Kaushik, N. K., Kaushik, N., Hammerschmid, D., Privat‐Maldonado, A., Backer, J. D., Shiratani, M., Choi, E. H., & Bogaerts, A. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.05.146 · Cited by 35
Mitochondria-targeted vitamin E succinate delivery for reversal of multidrug resistance
Liang, L., Peng, Y., & Qiu, L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.023 · Cited by 35
Chlorogenic Acid Enhances Doxorubicin-Mediated Cytotoxic Effect in Osteosarcoma Cells
Salzillo, A., Ragone, A., Spina, A., Naviglio, S., & Sapio, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168586 · Cited by 35
Born to Run? Diverse Modes of Epithelial Migration
Lu, P., & Lu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.704939 · Cited by 35
HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis
Chen, X., Chen, Y., Zhang, M., Cheng, H., Mai, H., Meng, Y., Xu, H., Yuan, X., Liu, S., & Wen, F. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04531-3 · Cited by 36
The Surprisingly Positive Effect of Zinc-Phthalocyanines With High Photodynamic Therapy Efficacy of Melanoma Cancer
Castro, K. A. D. F., Prandini, J. A., Biazzotto, J. C., Tomé, J. P. C., da Silva, R. S., & Lourenço, L. M. O. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.825716 · Cited by 35
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges
Zhang, J., Tang, M., & Shang, J. (2024) · Biomolecules · doi:10.3390/biom14020190 · Cited by 42
Bioactive metal-based nanomedicines for boosting anti-tumor immunity: Advance, challenge, and perspective
Pei, Z., Li, L., Yang, N., Sun, S., Jiang, N., & Cheng, L. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215969 · Cited by 34
Actin-related protein 2/3 complex subunit 1B promotes ovarian cancer progression by regulating the AKT/PI3K/mTOR signaling pathway
Ke, M., Zhu, H., Lin, Y. W., Zhang, Y., Tang, T., Xie, Y., Chen, Z., Wang, X., & Shen, Y. L. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2024-0025 · Cited by 34
Breaking barriers: we need a multidisciplinary approach to tackle cancer drug resistance
Ingham, J., Ruan, J.-L., & Coelho, M. A. (2025) · BJC Reports · doi:10.1038/s44276-025-00129-2 · Cited by 36
Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers
(2025) · doi:10.1038/s41467-025-57181-2 · Cited by 34
Immune-related genes in tumor-specific CD4+ and CD8+ T cells in colon cancer
Xi, Y., Wu, W., Pan, Y., Zhou, Q., Xu, J., & Han, S. (2020) · BMC Cancer · doi:10.1186/s12885-020-07075-x · Cited by 34
7-Hydroxycoumarins Are Affinity-Based Fluorescent Probes for Competitive Binding Studies of Macrophage Migration Inhibitory Factor
Xiao, Z., Chen, D., Song, S., van der Vlag, R., van der Wouden, P. E., van Merkerk, R., Cool, R. H., Hirsch, A. K. H., Melgert, B. N., Quax, W. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01160 · Cited by 34
Cancer theranostic platforms based on injectable polymer hydrogels
Wang, F., Chen, J., Liu, J., & Zeng, H. (2021) · Biomaterials Science · doi:10.1039/d0bm02149k · Cited by 34
Long Non-Coding RNAs in Multidrug Resistance of Glioblastoma
Mahinfar, P., Baradaran, B., Davoudian, S., Vahidian, F., Cho, W. C. S., & Mansoori, B. (2021) · Genes · doi:10.3390/genes12030455 · Cited by 34
TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment
Guo, S., Bai, X., Shi, S., Deng, Y., Kang, X., & An, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010930 · Cited by 34
Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
Yuan, P., Yang, F., Liew, S. S., Yan, J., Dong, X., Wang, J., Du, S., Mao, X., Gao, L., & Yao, S. Q. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121376 · Cited by 34
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors
Laurent, P.-A., Morel, D., Meziani, L., Depil, S., & Deutsch, É. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2158013 · Cited by 34
Androgen receptor is a determinant of melanoma targeted drug resistance
Samarkina, A., Youssef, M. K., Ostano, P., Ghosh, S., Ma, M., Tassone, B., Proust, T., Chiorino, G., Levesque, M. P., Goruppi, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42239-w · Cited by 37
The complex relationship between multiple drug resistance and the tumor pH gradient: a review
Koltai, T. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2021.134 · Cited by 33
A Small Sugar Molecule with Huge Potential in Targeted Cancer Therapy
Pastuch-Gawołek, G., Szreder, J., Domińska, M., Pielok, M., Cichy, P., & Grymel, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030913 · Cited by 36
Targeted drug delivery system inspired by macropinocytosis
Jiang, G., Wei, C., Chen, Y., Lyu, Y., Huang, J., Chen, H., & Gao, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.06.011 · Cited by 34
The evidence for repurposing anti-epileptic drugs to target cancer
Aroosa, M., Malik, J. A., Ahmed, S., Bender, O., Ahemad, N., & Anwar, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08568-1 · Cited by 33
Mirabegron displays anticancer effects by globally browning adipose tissues
Sun, X., Sui, W., Mu, Z., Xie, S., Deng, J., Li, S., Seki, T., Wu, J., Xu, J., He, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-43350-8 · Cited by 36
Cancer Drug Resistance: Targeting Proliferation or Programmed Cell Death
Sazonova, E. V., Yapryntseva, M. A., Pervushin, N. V., Tsvetcov, R. I., Zhivotovsky, B., & Kopeina, G. S. (2024) · Cells · doi:10.3390/cells13050388 · Cited by 33
KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC
Li, J., Shi, D., Li, S., Shi, X., Liu, Y., Zhang, Y., Wang, G., Zhang, C., Xia, T., Piao, H., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06563-3 · Cited by 36
Propolis Stands out as a Multifaceted Natural Product: Meta-Analysis on Its Sources, Bioactivities, Applications, and Future Perspectives
Ayad, A. S., Benchaabane, S., Daas, T., Smagghe, G. J., & Loucif‐Ayad, W. (2025) · Life · doi:10.3390/life15050764 · Cited by 38
Strategies to overcome resistance to immune checkpoint blockade in lung cancer
Attili, I., Tarantino, P., Passaro, A., Stati, V., Curigliano, G., & de Marinis, F. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.02.035 · Cited by 33
Hypoxia-Activated Prodrug Enabling Synchronous Chemotherapy and HIF-1α Downregulation for Tumor Treatment
Luo, X., Li, A., Chi, X., Lin, Y., Liu, X., Zhang, L., Su, X., Yin, Z., Lin, H., & Gao, J. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00131 · Cited by 33
Disulfide bond based cascade reduction-responsive Pt(IV) nanoassemblies for improved anti-tumor efficiency and biosafety
Kuang, X., Chi, D., Li, J., Guo, C., Yang, Y., Zhou, S., Luo, C., Liu, H., He, Z., & Wang, Y. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111766 · Cited by 33
Progress in Redirecting Antiparasitic Drugs for Cancer Treatment
Huang, H., He, Q., Bing-hua, G., Xu, X., Wu, Y., & Li, X. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s308973 · Cited by 35
CRISPR/Cas9 nanoeditor of double knockout large fragments of E6 and E7 oncogenes for reversing drugs resistance in cervical cancer
Li, X., Guo, M., Hou, B., Zheng, B., Wang, Z., Huang, M., Xu, Y., Chang, J. K., & Wang, T. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00970-w · Cited by 33
Photothermal and Enhanced Photocatalytic Therapies Conduce to Synergistic Anticancer Phototherapy with Biodegradable Titanium Diselenide Nanosheets
Duo, Y., Luo, G., Li, Z., Chen, Z., Li, X., Jiang, Z., Yu, B., Huang, H., Sun, Z., & Yu, X. (2021) · Small · doi:10.1002/smll.202103239 · Cited by 33
Cancer progression as a learning process
Shomar, A., Barak, O., & Brenner, N. (2022) · iScience · doi:10.1016/j.isci.2022.103924 · Cited by 33
An Intelligent Nanovehicle Armed with Multifunctional Navigation for Precise Delivery of Toll‐Like Receptor 7/8 Agonist and Immunogenic Cell Death Amplifiers to Eliminate Solid Tumors and Trigger Durable Antitumor Immunity
Hao, Y., Li, H., Zhao, H., Liu, Y., Ge, X., Li, X., Chen, H., Yang, A., Zou, J., Li, X., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102739 · Cited by 33
Gold nanostructure-mediated delivery of anticancer agents: Biomedical applications, reversing drug resistance, and stimuli-responsive nanocarriers
Entezari, M., Abad, G. G. Y., Sedghi, B., Ettehadi, R., Asadi, S., Beiranvand, R., Haratian, N., Karimian, S. S., Jebali, A., Khorrami, R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115673 · Cited by 35
USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2
Chandrasekaran, A. P., Kaushal, K., Park, C., Kim, K.-S., & Ramakrishna, S. (2021) · Theranostics · doi:10.7150/thno.63806 · Cited by 33
Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
Hatzl, S., Perfler, B., Wurm, S., Uhl, B., Quehenberger, F., Ebner, S., Troppmair, J., Reinisch, A., Wölfler, A., Sill, H., et al. (2020) · Cancers · doi:10.3390/cancers12020496 · Cited by 32
Emerging roles of epithelial-mesenchymal plasticity in invasion-metastasis cascade and therapy resistance
Garg, M. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-10003-5 · Cited by 33
Nanomedicine/materdicine-enabled sonocatalytic therapy
Chang, M., Zhang, L., Wang, Z., Chen, L., Dong, Y., Yang, J., & Chen, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115160 · Cited by 32
Overcoming challenges in cancer treatment: Nano‐enabled photodynamic therapy as a viable solution
Rajan, S. S., Chandran, R., & Abrahamse, H. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1942 · Cited by 35
Endothelin-1 and Its Role in Cancer and Potential Therapeutic Opportunities
Harrison, M., Zinovkin, D. A., & Pranjol, M. Z. I. (2024) · Biomedicines · doi:10.3390/biomedicines12030511 · Cited by 34
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial
Zañudo, J. G. T., Barroso‐Sousa, R., Jain, E., Jin, Q., Li, T., Buendia-Buendia, J. E., Pereslete, A., Abravanel, D. L., Ferreira, A. R., Wrabel, E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45835-6 · Cited by 37
Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer
He, T., Cheng, C., Qiao, Y., Cho, H., YOUNG, E. A., Mannan, R., Mahapatra, S., Miner, S. J., Zheng, Y., Kim, N. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322563121 · Cited by 30
Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors
Fabro, F., Lamfers, M. L. M., & Leenstra, S. (2022) · Cancers · doi:10.3390/cancers14030600 · Cited by 33
The Regulatory Roles of Mitochondrial Calcium and the Mitochondrial Calcium Uniporter in Tumor Cells
Zhang, L., Qi, J., Zhang, X., Zhao, X., An, P., Luo, Y., & Luo, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126667 · Cited by 32
HIF in Gastric Cancer: Regulation and Therapeutic Target
Li, M., Guan, L., Yang, X., Yin, W., Lv, G., & Wang, S. (2022) · Molecules · doi:10.3390/molecules27154893 · Cited by 33
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 35
Bcl-2 family inhibitors sensitize human cancer models to therapy
Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 35
Ru(II)‐Cyanine Complexes as Promising Photodynamic Photosensitizers for the Treatment of Hypoxic Tumours with Highly Penetrating 770 nm Near‐Infrared Light
Gandioso, A., Izquierdo‐García, E., Mesdom, P., Arnoux, P., Demeubayeva, N., Bürckel, P., Saubaméa, B., Bosch, M., Frochot, C., Marchán, V., et al. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301742 · Cited by 32
Bioactive sesquiterpenes from Inula helenium
Zheng, X., Wu, Z. Y., Xu, J., Zhang, X., Tu, Y., Lei, J., Yuan, R., Cheng, H., Wang, Q., & Yu, J. J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105066 · Cited by 31
Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
Yi, W., Yan, D., Wang, D., & Li, Y. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0009 · Cited by 31
O‐GlcNAcylation promotes topoisomerase IIα catalytic activity in breast cancer chemoresistance
Liu, Y., Yu, K., Zhang, K., Niu, M., Chen, Q., Liu, Y., Wang, L., Zhang, N., Li, W., Zhong, X., et al. (2023) · EMBO Reports · doi:10.15252/embr.202256458 · Cited by 31
Covalent–Organic Framework-Based Materials in Theranostic Applications: Insights into Their Advantages and Challenges
Kaur, H., Siwal, S. S., Saini, R. V., & Thakur, V. K. (2024) · ACS Omega · doi:10.1021/acsomega.3c08456 · Cited by 32
Creation of a point-of-care therapeutics sensor using protein engineering, electrochemical sensing and electronic integration
Cai, R., Ngwadom, C., Saxena, R., Soman, J., Bruggeman, C., Hickey, D. P., Verduzco, R., & Ajo-Franklin, C. M. (2024) · Nature Communications · doi:10.1038/s41467-024-45789-9 · Cited by 31
Advancements in Circulating Tumor Cell Research: Bridging Biology and Clinical Applications
Salu, P., & Reindl, K. M. (2024) · Cancers · doi:10.3390/cancers16061213 · Cited by 31
Functions and inhibitors of CHK1 in cancer therapy
Jiang, K., Deng, M., Du, W., Liu, T., Li, J., & Zhou, Y. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100185 · Cited by 33
The role of mesenchymal stem cells in cancer and prospects for their use in cancer therapeutics
Tang, J., Chen, Y., Wang, C., Xia, Y., Yu, T., Tang, M., Meng, K., Yin, L., Yang, Y., Shen, L., et al. (2024) · MedComm · doi:10.1002/mco2.663 · Cited by 31
Discovery of Novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based Derivatives as Potent CDK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors and Hematological Malignancies
Saidahmatov, A., Li, J., Xu, S., Hu, X., Gao, X., Kan, W., Gao, L., Li, C., Shi, Y., Li, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00837 · Cited by 32
Dimerized Pentamethine Cyanines for Synergistically Boosting Photodynamic/Photothermal Therapy
Huang, H., Liu, Q., Zhu, J., Tong, Y., Huang, D., Zhou, D., Long, S., Wang, L., Li, M., Chen, X., et al. (2024) · Aggregate · doi:10.1002/agt2.706 · Cited by 31
Exosome-driven nano-immunotherapy: revolutionizing colorectal cancer treatment
Lahouty, M., Fadaee, M., Shanehbandi, D., & Kazemi, T. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-10157-9 · Cited by 31
Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells
Ao, J., Chiba, T., Shibata, S., Kurosugi, A., Qiang, N., Ma, Y., Kan, M., Iwanaga, T., Sakuma, T., Kanzaki, H., et al. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.02.097 · Cited by 31
Pancreatic Cancer Small Extracellular Vesicles (Exosomes): A Tale of Short- and Long-Distance Communication
Waldenmaier, M., Seibold, T., Seufferlein, T. T. W., & Eiseler, T. (2021) · Cancers · doi:10.3390/cancers13194844 · Cited by 31
Association between Handgrip Strength and the Systemic Immune-Inflammation Index: A Nationwide Study, NHANES 2011–2014
Wu, D., Gao, X., Shi, Y., Wang, H., Wang, W., Li, Y., & Zheng, Z. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192013616 · Cited by 32
A hyaluronic acid modified cuprous metal-organic complex for reversing multidrug resistance via redox dyshomeostasis
Wan, Y., Chen, Z., Wang, Y., Zhao, W., Pei, Z., Pu, L., Lv, Y., Li, J., Li, J., & Pei, Y. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120762 · Cited by 31
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Dunbar, A. J., Bowman, R. L., Park, Y. C., O’Connor, K., Izzo, F., Myers, R. M., Karzai, A., Zaroogian, Z., Kim, W. J., Fernández-Maestre, I., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0952 · Cited by 34
Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
Pathak, R., & Villaflor, V. M. (2021) · Cancers · doi:10.3390/cancers13184641 · Cited by 30
Cancer cell-autonomous cGAS-STING response confers drug resistance
Lv, Q.-M., Lei, H.-M., Wang, S., Zhang, K., Tang, Y., Shen, Y. H., Lu, L., Chen, H., & Zhu, L. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.005 · Cited by 31
Nanomedicine Strategies for Targeting Tumor Stroma
Su, M., Nethi, S. K., Dhanyamraju, P. K., & Prabha, S. (2023) · Cancers · doi:10.3390/cancers15164145 · Cited by 32
Targosomes: Anti-HER2 PLGA nanocarriers for bioimaging, chemotherapy and local photothermal treatment of tumors and remote metastases
Komedchikova, E. N., Kolesnikova, O. A., Syuy, A. V., Volkov, V. S., Deyev, S. M., Nikitin, M. P., & Shipunova, V. O. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.036 · Cited by 30
Bioengineered Nanomaterials for siRNA Therapy of Chemoresistant Cancers
Sanati, M., Figueroa‐Espada, C. G., Han, E. L., Mitchell, M. J., & Yavari, S. A. (2024) · ACS Nano · doi:10.1021/acsnano.4c11259 · Cited by 33
Mitochondrial-Targeted Multifunctional Platinum-Based Nano “Terminal-Sensitive Projectile” for Enhanced Cancer Chemotherapy Efficacy
Zhang, Q., Lin, J., Li, J., Zhou, Y., ZhiQiang, B., Yang, H., Lu, W., Lu, T., Qian, R., Yang, X., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c15456 · Cited by 30
Engineering nanoplatforms of bacterial outer membrane vesicles to overcome cancer therapy resistance
Chai, Q., Li, D., Zhang, M., Gu, Y., Li, A., Wu, X., Liu, X., & Liu, J. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101277 · Cited by 32
Advances in applied supramolecular technologies 2021–2025
Balderston, D. E., Feo, E., Leonescu, A., Stevens, M., Wilmshurst, A. M., Gale, P. A., Haynes, C. J. E., Williams, G. T., & Hiscock, J. R. (2025) · Chemical Society Reviews · doi:10.1039/d4cs01037j · Cited by 30
MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy
Bitaraf, A., Zafarani, A., Jahandideh, P., Hakak‐Zargar, B., Haghi, A., Asgaritarghi, G., & Babashah, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02415-6 · Cited by 37
Detection of genome-wide low-frequency mutations with Paired-End and Complementary Consensus Sequencing (PECC-Seq) revealed end-repair-derived artifacts as residual errors
You, X.-Y., Thiruppathi, S., Liu, W.-Y., Cao, Y.-Y., Naito, M., Furihata, C., Honma, M., Luan, Y., & Suzuki, T. (2019) · Archives of Toxicology · doi:10.1007/s00204-020-02832-0 · Cited by 23
Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review
Ganai, A. M., Pathan, T. K., Hampannavar, G. A., Pawar, C. D., Obakachi, V. A., Kushwaha, B., Kushwaha, N. D., & Karpoormath, R. V. (2021) · ChemistrySelect · doi:10.1002/slct.202004591 · Cited by 30
Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells
Ma, Q., Shen, M.-O., Han, N., Xu, H., Peng, X., Li, Q., Yu, T., Li, L., Xu, X. M., Liu, B., et al. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102645 · Cited by 30
Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway
Zhang, J., Xu, H., Cho, W. C. S., Cheuk, W., Li, Y., Huang, Q., Yang, W., Xian, Y., & Lin, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02270-z · Cited by 30
Spatial Distribution Control of Antimicrobial Peptides through a Novel Polymeric Carrier for Safe and Efficient Cancer Treatment
Kang, Z., Wang, C., Zhang, Z., Liu, Q., Zheng, Y., Zhao, Y., Pan, Z., Li, Q., Shi, L., & Liu, Y. (2022) · Advanced Materials · doi:10.1002/adma.202201945 · Cited by 31
Noncoding RNAs in pyroptosis and cancer progression: Effect, mechanism, and clinical application
Zhang, M. H., Dang, P., Liu, Y., Qiao, B., & Sun, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982040 · Cited by 29
Enabling perfusion through multicellular tumor spheroids promoting lumenization in a vascularized cancer model
Park, J., Kim, S., Hong, J., & Jeon, J. S. (2022) · Lab on a Chip · doi:10.1039/d2lc00597b · Cited by 31
Lipid-polymer hybrid nanoparticle with cell-distinct drug release for treatment of stemness-derived resistant tumor
Shen, S., Li, T., Fan, J., Shao, Q., Dong, H., Xu, X., & Mo, R. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.009 · Cited by 30
Extrachromosomal circular DNA in colorectal cancer: biogenesis, function and potential as therapeutic target
Chen, Y., Qiu, Q., She, J., & Yu, J. Q. (2023) · Oncogene · doi:10.1038/s41388-023-02640-7 · Cited by 30
A tumor-targeting fluorescent probe for ratiometric imaging of pH and improving PDT/PTT synergistic therapy
Gu, Q.-S., Li, T., Wang, W.-X., Wang, Z.-Q., Liu, Q.-R., Mao, G., Li, Y., & Li, C. (2023) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2023.134287 · Cited by 30
The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells
Gao, H.-L., Cui, Q.-B., Wang, J.-Q., Ashby, C., Chen, Y.-C., Shen, Z.-R., & Chen, Z.-S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1235285 · Cited by 29
The pharmacological effects of Berberine and its therapeutic potential in different diseases: Role of the phosphatidylinositol 3‐kinase/ AKT signaling pathway
Khezri, M. R., Mohammadipanah, S., & Ghasemnejad‐Berenji, M. (2023) · Phytotherapy Research · doi:10.1002/ptr.8040 · Cited by 32
The recent progress of deep-learning-based in silico prediction of drug combination
Liu, H., Fan, Z., Lin, J., Yang, Y., Ran, T., & Chen, H. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103625 · Cited by 29
WDR4/TRIM28 is a novel molecular target linked to lenvatinib resistance that helps retain the stem characteristics in hepatocellular carcinomas
Han, W.-Y., Wang, J., Zhao, J., Zheng, Y.-M., Chai, X., Gao, C., Cai, J.-B., Ke, A., Fan, J., Gao, P., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216259 · Cited by 29
Shedding Light on Chemoresistance: The Perspective of Photodynamic Therapy in Cancer Management
Cabral, F. V., Quílez-Alburquerque, J., Roberts, H. J., & Hasan, T. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073811 · Cited by 29

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks